Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer.

Citation: Escobar Z, Bjartell A, Canesin G, Evans-Axelsson S, Sterner O, Hellsten R, Johansson MH.: Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. J Med Chem, Volume 59 (10), 2016
Authors: Bjartell A, Canesin G, Escobar Z, Evans-Axelsson S, Hellsten R, Johansson MH., Sterner O
Journal: J Med Chem
Year: 2016
DOI: 10.1021/acs.jmedchem.5b01814
PubMed: 27111731
Machine-readable: REST API RDF

Publication